Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$64.26
Market cap
$199.21B
P/E Ratio
30.75
Dividend/share
$1.49
EPS
$2.09
Enterprise value
$225.97B
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
Highlights
AZN's price to earnings (P/E) is 77% lower than its 5-year quarterly average of 132.3 and 14% lower than its last 4 quarters average of 35.8
The company's gross profit rose by 15% YoY and by 2.7% QoQ
AZN's debt is up by 10% year-on-year but it is down by 6% since the previous quarter
Key stats
What are the main financial stats of AZN
Market
Valuations
Earnings
Shares outstanding
3.1B
Market cap
$199.21B
Enterprise value
$225.97B
Price to earnings (P/E)
30.75
Price to book (P/B)
4.89
Price to sales (P/S)
3.89
EV/EBIT
23.37
EV/EBITDA
14.72
EV/Sales
4.41
Revenue
$51.21B
EBIT
$9.67B
EBITDA
$15.35B
Free cash flow
$9.65B
Per share
Balance sheet
Liquidity
EPS
$2.09
Free cash flow per share
$3.11
Book value per share
$13.14
Revenue per share
$16.52
TBVPS
$14.32
Total assets
$104.92B
Total liabilities
$64.12B
Debt
$31.56B
Equity
$40.72B
Working capital
-$1.77B
Debt to equity
0.78
Current ratio
0.93
Quick ratio
0.68
Net debt/EBITDA
1.74
Margins
Efficiency
Dividend
EBITDA margin
30%
Gross margin
80.9%
Net margin
12.7%
Operating margin
18%
Return on assets
6.3%
Return on equity
16.6%
Return on invested capital
23.6%
Return on capital employed
12.2%
Return on sales
18.9%
Dividend yield
2.31%
DPS
$1.49
Payout ratio
71.1%
AZN stock price
How has the Astrazeneca stock price performed over time
Intraday
1.68%
1 week
-1.2%
1 month
-17.02%
1 year
-0.03%
YTD
-4.59%
QTD
-17.52%
Financial performance
How have Astrazeneca's revenue and profit performed over time
Revenue
$51.21B
Gross profit
$41.42B
Operating income
$9.2B
Net income
$6.5B
Gross margin
80.9%
Net margin
12.7%
The company's gross profit rose by 15% YoY and by 2.7% QoQ
Astrazeneca's revenue has increased by 14% YoY and by 4.2% QoQ
AZN's operating income is up by 14% year-on-year
AZN's net income is up by 10% year-on-year
Growth
What is Astrazeneca's growth rate over time
Valuation
What is Astrazeneca stock price valuation
P/E
30.75
P/B
4.89
P/S
3.89
EV/EBIT
23.37
EV/EBITDA
14.72
EV/Sales
4.41
AZN's price to earnings (P/E) is 77% lower than its 5-year quarterly average of 132.3 and 14% lower than its last 4 quarters average of 35.8
Astrazeneca's EPS has increased by 10% YoY
The stock's price to book (P/B) is 31% less than its 5-year quarterly average of 7.1 and 14% less than its last 4 quarters average of 5.7
AZN's equity is up by 9% year-on-year and by 3.1% since the previous quarter
The stock's price to sales (P/S) is 21% less than its 5-year quarterly average of 4.9 and 17% less than its last 4 quarters average of 4.7
Astrazeneca's revenue has increased by 14% YoY and by 4.2% QoQ
Efficiency
How efficient is Astrazeneca business performance
Astrazeneca's return on invested capital has decreased by 4.8% QoQ
The company's return on equity rose by 3.8% YoY
The return on assets is up by 3.3% year-on-year
Astrazeneca's return on sales has increased by 2.2% YoY
Dividends
What is AZN's dividend history
DPS
$1.49
Dividend yield
2.31%
Payout ratio
71.1%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Astrazeneca financials performed over time
The company's total assets is 64% higher than its total liabilities
AZN's current ratio is up by 18% YoY and by 4.5% from the previous quarter
The quick ratio rose by 13% year-on-year and by 3% since the previous quarter
AZN's debt is 22% smaller than its equity
AZN's debt is up by 10% year-on-year but it is down by 6% since the previous quarter
AZN's equity is up by 9% year-on-year and by 3.1% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.